Mantle Cell Lymphoma

Amitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.

In an interview with Targeted Oncology, Amitkumar Mehta, MD, discussed the findings for the PI3Kδ inhibitor parsaclisib as treatment of patients with relapsed/refractory mantle cell lymphoma.

A new multi-analyte prognostic assay has demonstrated the potential to risk-stratifying patients with mantle cell lymphoma based on the particular molecular signature of an individual patient’s cancer, according to a new study.

Patients with relapsed or refractory mantle cell lymphoma treated with a daily dose of parsaclisib demonstrated significant activity and tolerability for the next-generation PI3Kδ inhibitor, according to findings from the phase 2 CITADEL-205 trial.

Preetesh Jain, MD, PhD, discusses the efficacy and predictors of response with ibrutinib and rituximab in combination as treatment of patients with previously untreated mantle cell lymphoma.

New data show patients with mantle cell lymphoma who were treated with ibrutinib in a community setting had similar outcomes to patients given the Bruton’s tyrosine kinase inhibitor in a clinical trial setting, a retrospective study showed.

Matthew Davids, MD, MMSc, discusses the prognosis expected for patients with mantle cell lymphoma, as well as chronic lymphocytic leukemia, in the relapsed/refractory population.

Investigators reported findings for 6 patients with mantle cell lymphoma who were treated in the ZUMA-2 clinical trial and progressed following treatment with therapy brexucabtagene autoleucel.

Results from the study were published in Blood and showed that obinutuzumab plus ibrutinib and venetoclax as treatment of patients with relapsed and untreated mantle cell lymphoma achieved high response rates with favorable tolerability.

During the Targeted Oncology Case Based Peer Perspectives event, Javier L. Munoz, MD, Hematologist/Oncologist Director, Lymphoma Program Mayo Clinic, discussed the case of 60-year-old patient with peripheral T-cell lymphoma.

The treatment landscape of mantle cell lymphoma has been enriched with the development of several targeted therapies, but patients considered to have high-risk disease tend to have a worse prognosis, despite the latest development in the field.

Michael Wang, MD, discusses current and upcoming treatments being investigated for patients with mantle cell lymphoma.

“The landscape has completely changed as a consequence of COVID[-19]," says Robert Marcus, MA, FRCP, FRCPath.

Obinutuzumab with dexamethasone plus high-dose cytarabine and cisplatin generated good activity for inducing bone marrow minimal residual disease negativity in patients with mantle cell lymphoma who are eligible for transplant.

In an interview with Targeted Oncology, Peter Martin, MD, discusses the current mantle cell lymphoma treatment landscape and the future of the field.

Michael Wang, MD, discusses potential upcoming treatment options for patients with mantle cell lymphoma, including targeted therapies and chimeric antigen receptor T cells.

The combination of ibrutinib and venetoclax will be tested as frontline therapy in previously untreated patients with mantle cell lymphoma as part of the 3-part phase 3 SYMPATICO trial.

The FDA granted a Fast Track and Orphan Drug designation to VLS-101 for the treatment of patients with mantle cell lymphoma.

Javier Munoz, MD, MS, FACP, of the Mayo Clinic, considers the appropriateness for CAR T-cell therapy for a 66-year-old woman with relapsed/refractory mantle cell lymphoma.